Antineoplastic Combined Chemotherapy Protocols
"Antineoplastic Combined Chemotherapy Protocols" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
| Descriptor ID |
D000971
|
| MeSH Number(s) |
E02.183.750.500 E02.319.077.500 E02.319.310.037
|
| Concept/Terms |
Antineoplastic Combined Chemotherapy Protocols- Antineoplastic Combined Chemotherapy Protocols
- Combined Antineoplastic Agents
- Antineoplastic Agents, Combined
- Agent, Combined Antineoplastic
- Agents, Combined Antineoplastic
- Antineoplastic Agent, Combined
- Combined Antineoplastic Agent
- Antineoplastic Combined Chemotherapy Regimens
- Drug Combinations, Antineoplastic
- Anticancer Drug Combinations
- Anticancer Drug Combination
- Drug Combination, Anticancer
- Drug Combinations, Anticancer
- Antineoplastic Drug Combinations
- Antineoplastic Drug Combination
- Combinations, Antineoplastic Drug
- Drug Combination, Antineoplastic
Antineoplastic Chemotherapy Protocols- Antineoplastic Chemotherapy Protocols
- Antineoplastic Chemotherapy Protocol
- Chemotherapy Protocol, Antineoplastic
- Protocol, Antineoplastic Chemotherapy
- Protocols, Antineoplastic Chemotherapy
- Cancer Chemotherapy Protocols
- Cancer Chemotherapy Protocol
- Chemotherapy Protocol, Cancer
- Chemotherapy Protocols, Cancer
- Protocol, Cancer Chemotherapy
- Protocols, Cancer Chemotherapy
- Chemotherapy Protocols, Antineoplastic
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Combined Chemotherapy Protocols".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Combined Chemotherapy Protocols".
This graph shows the total number of publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in this website by year, and whether "Antineoplastic Combined Chemotherapy Protocols" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 8 | 1 | 9 |
| 1996 | 8 | 2 | 10 |
| 1997 | 7 | 1 | 8 |
| 1998 | 11 | 3 | 14 |
| 1999 | 9 | 2 | 11 |
| 2000 | 8 | 3 | 11 |
| 2001 | 5 | 3 | 8 |
| 2002 | 9 | 7 | 16 |
| 2003 | 8 | 11 | 19 |
| 2004 | 7 | 7 | 14 |
| 2005 | 14 | 6 | 20 |
| 2006 | 14 | 4 | 18 |
| 2007 | 15 | 5 | 20 |
| 2008 | 25 | 8 | 33 |
| 2009 | 20 | 8 | 28 |
| 2010 | 24 | 12 | 36 |
| 2011 | 20 | 14 | 34 |
| 2012 | 19 | 7 | 26 |
| 2013 | 21 | 6 | 27 |
| 2014 | 36 | 13 | 49 |
| 2015 | 30 | 14 | 44 |
| 2016 | 17 | 22 | 39 |
| 2017 | 28 | 18 | 46 |
| 2018 | 41 | 19 | 60 |
| 2019 | 41 | 15 | 56 |
| 2020 | 31 | 23 | 54 |
| 2021 | 18 | 33 | 51 |
| 2022 | 9 | 45 | 54 |
| 2023 | 5 | 44 | 49 |
| 2024 | 28 | 24 | 52 |
| 2025 | 24 | 3 | 27 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in Profiles.
-
Ibrutinib plus rituximab vs ibrutinib monotherapy in patients with Waldenstr?m macroglobulinemia: a pooled analysis. Blood Adv. 2025 Sep 23; 9(18):4705-4715.
-
Capivasertib cost-effectiveness in treating advanced breast cancer: A US health care perspective. J Manag Care Spec Pharm. 2025 Sep; 31(9):900-908.
-
Neoadjuvant HER2-targeted regimens with or without anthracyclines for HER2-positive inflammatory breast cancer: a multicenter retrospective study. Breast Cancer Res Treat. 2025 Nov; 214(1):69-77.
-
Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b study. Cancer. 2025 Aug 01; 131(15):e70022.
-
Combinatorial therapy regimens targeting preclinical models of melanoma resistant to immune checkpoint blockade. J Clin Invest. 2025 Sep 16; 135(18).
-
Real-world effectiveness of palbociclib plus endocrine therapy in HR+/HER2- advanced breast cancer: final results from the POLARIS trial. Oncologist. 2025 Jul 04; 30(7).
-
Relapse patterns among children and adolescents with Kaposi sarcoma in Malawi. Pediatr Hematol Oncol. 2025 Aug; 42(5):276-286.
-
Anlotinib combined with benmelstobart as a chemo-free first-line treatment in advanced esophageal squamous cell carcinoma: an exploratory multicenter, single-arm phase II clinical trial. Mol Cancer. 2025 Jun 11; 24(1):175.
-
National trends in neoadjuvant systemic therapy utilization in patients with early-stage HER2-positive breast cancer from 2016-2021: The impact of the KATHERINE trial. Breast Cancer Res Treat. 2025 Aug; 212(3):531-543.
-
Polo-like kinase 1 inactivation enhances PI3K inhibition-mediated apoptosis of NOTCH1-mutant head and neck squamous cell carcinoma. Cancer Lett. 2025 Aug 10; 625:217814.